{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:30:15Z","timestamp":1787311815871,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Assess changes in symptoms of anxiety, depression, and psychosocial or spiritual distress before and after ketamine-assisted psychotherapy (KAP) in individuals with problematic substance use (PSU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart review was performed on participant data from two five-year prospective outcomes studies: the AIMS Medical Outcomes Study (AMOS) and the AIMS Cancer Outcomes Study (ACOS). The efficacy of KAP for anxiety, depression, and psychosocial or spiritual well being was assessed in patients with current, past, or high risk of substance use disorder. Validated psychometrics utilized were Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), and the National Institute of Health - Healing Experiences of All Life Stressors (NIH-HEALS) questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between November 1, 2020 and October 31, 2022, a total of 18 patients identified with problematic substance use completed at least one KAP session and at least one baseline and post-KAP metric questionnaire. The PSU subpopulation average score changes were as follows: GAD-7 (-6.71 \u00b1 9.15,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914); PHQ-9 (-7.44 \u00b1 5.42,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916); and NIH-HEALS (5.13 \u00b1 13.64,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915). The average score changes for the KAP population of enrolled subjects were as follows: GAD-7 (-2.45 \u00b1 6.01,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009104); PHQ-9 (-3.02 \u00b1 6.01,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009111); and NIH-HEALS (2.93 \u00b1 11.91,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200986). A comparison of average score changes (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05) between the PSU subpopulation and KAP population were as follows: GAD-7 (0.0219, 95% C.I. 1.37-8.11); PHQ-9 (0.0062, 95% C.I. 1.28-7.56); and NIH-HEALS (0.5197, 95% C.I. 8.96-4.56). For patients with PSU, results demonstrate statistically significant improvements in anxiety and depression symptoms after at least one KAP session. Average NIH-HEALS scores increased, though not by a statistically significant amount. Compared to the general population of enrolled KAP patients during this period, patients with PSU reported significantly greater average reductions in GAD-7 and PHQ-9 scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Undergoing one to six ketamine-assisted psychotherapy (KAP) sessions was associated with improved anxiety and depression ratings in patients with problematic substance use. Two-thirds of participants also experienced improved psychosocial and spiritual well-being. The use of KAP may be important to consider as a therapy for reducing anxiety and depression symptoms in patients with problematic substance use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1160442","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:54:30Z","timestamp":1693443270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Reductions in anxiety and depression symptoms in a subset of outpatients with problematic substance use who received ketamine-assisted psychotherapy: a two-year retrospective chart review"],"prefix":"10.3389","volume":"14","author":[{"given":"Emily","family":"Whinkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therry Rose J.","family":"Eparwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle C.","family":"Julseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"ref1","article-title":"British Columbia Ministry of Health services","year":"2004"},{"key":"ref2","year":"2022"},{"key":"ref3","year":""},{"key":"ref4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.neubiorev.2021.05.006","article-title":"Therapeutic potential of ketamine for alcohol use disorder","volume":"126","author":"Worrell","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7620","DOI":"10.12998\/wjcc.v9.i26.7620","article-title":"Spirituality, religiousness, and mental health: a review of the current scientific evidence","volume":"9","author":"Lucchetti","year":"2021","journal-title":"World J Clin Cases"},{"key":"ref6","article-title":"NCDAS","year":"2023"},{"key":"ref7","volume-title":"Drug overdose death rates. National Institute on Drug Abuse","year":"2023"},{"key":"ref8","volume-title":"Alcohol-related deaths. Centers for Disease Control and Prevention","year":"2022"},{"key":"ref9","article-title":"AIMS Medical Outcomes Study clinicaltrialsgov","year":"2023"},{"key":"ref10","article-title":"Advanced integrative oncology treatment for adult and pediatric patients with Cancer: a prospective outcomes study. clinicaltrials.gov","year":"2023"},{"key":"ref11","volume-title":"American Board of Physician Specialties","year":""},{"key":"ref12","volume-title":"The six principles of naturopathic medicine. AANMC","year":""},{"key":"ref13","volume-title":"Trends in visits to substance use disorder treatment facilities in 2020 - PMC","year":""},{"key":"ref14","doi-asserted-by":"publisher","first-page":"927703","DOI":"10.3389\/fphar.2022.927703","article-title":"Off-label and investigational drugs in the treatment of alcohol use disorder: a critical review","volume":"13","author":"Fischler","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref15","volume-title":"Mental-health needs have Washington in a state of crisis. UW Magazine \u2014 University of Washington Magazine","year":""},{"key":"ref16","article-title":"Ketamine","volume-title":"StatPearls","author":"Rosenbaum","year":"2017"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1192\/bjo.2021.1061","article-title":"Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review","volume":"8","author":"Walsh","year":"2021","journal-title":"BJPsych Open"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am J Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: evidence and potential mechanisms","volume":"142","author":"Ivan Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1017\/S1092852919001238","article-title":"Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature","volume":"25","author":"Banov","year":"2020","journal-title":"CNS Spectr"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s44192-022-00012-3","article-title":"Ketamine treatment for depression: a review","volume":"2","author":"Yavi","year":"2022","journal-title":"Discov Ment Health"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.2147\/DDDT.S221437","article-title":"Ketamine and depression: a narrative review","volume":"13","author":"Corriger","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.15585\/mmwr.mm6932a1","article-title":"Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic \u2014 United States, June 24\u201330, 2020","volume":"69","author":"Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/JPR.S360733","article-title":"Ketamine assisted psychotherapy: a systematic narrative review of the literature","volume":"15","author":"Drozdz","year":"2022","journal-title":"J Pain Res"},{"key":"ref26","volume-title":"Common comorbidities with substance use disorders research report. National Institutes on drug abuse (US)","year":"2020"},{"key":"ref27","author":"Abrams","year":"2015"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1160442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:54:36Z","timestamp":1693443276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1160442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":27,"alternative-id":["10.3389\/fpsyt.2023.1160442"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1160442","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]},"article-number":"1160442"}}